Senza (spinal cord stimulation device)

2021: Announcement of spinal cord stimulation device for severe diabetes complication

In mid-July 2021, Nevro introduced the world's first implantable spinal cord stimulation system Senza, designed to treat chronic pain in diabetic neuropathy.

Diabetic neuropathy is a condition arising from untreated or late detected diabetes mellitus, which manifests itself in degenerative damage to all elements of the nervous system. The Senza system uses high-frequency spinal cord stimulation to relieve chronic pain without paresthesia. The system operates regardless of the position of the patient's body, while, according to the developers, 16 contacts provide the widest possible coverage and provide a wide range of therapy programming capabilities. The remote control allows the patient to independently control and regulate the level of spinal cord stimulation. The estimated service life of the battery feeding the pulse generator is 10 years under normal conditions.

Senza (spinal cord stimulation device)

The safety and effectiveness of the spinal cord stimulation system with this device is confirmed by the results of the SENZA-PDN study, in which the new system surpassed all previously available treatments for diabetic neuropathy. According to this randomized trial, improvement was noted even in patients whose symptoms were immune to conventional therapy.

The company said it plans to immediately launch a commercial release of Senza in the United States under its newly introduced brand. Nevro expects that in 2021, revenue from the sale of these devices will be several million, most of which will be received in the fourth quarter. The company expects to receive the largest income in 2022 due to entering the markets of Great Britain, Germany and Australia.^[1]

Notes